University of Baghdad Pilot Clinical Trial: Ivermectin plus Hydroxychloroquine & Azithromycin Superior to No Ivermectin

University of Baghdad Pilot Clinical Trial Ivermectin plus Hydroxychloroquine & Azithromycin Superior to No Ivermectin

The TrialSite Network eagerly awaited a pilot clinical trial investigating the safety and efficacy of Ivermectin sponsored by the University of Baghdad in Iraq. Led by Professor Faiq Gorial, this study target 100 patients in a Phase 1 clinical trial investigating the efficacy of add on therapy of a single dose of Ivermectin to hydroxychloroquine (HCQ) and azithromycin (AZT) in COVID-19 patients versus a non-Ivermectin group just having HCQ and AZT. A couple weeks ago, Professor Gorial communicate with TrialSite News that he was trying to publish his results. In the meantime, they have been posted to the medRxiv preprint server, so they are still not “peer reviewed.” The pilot trial conducted on hospitalized adult patients with mild to moderate COVID-19 diagnosed according to WHO interim guidance. 16 patients received a single dose of IVM 200Mcg/kg on admission day as add on therapy to HCQ and AZT and were compared with 71 controls receiving HCQ and AZT matched in age, gender, clinical features, and comorbidities. The University of Baghdad researchers concluded that adding the use of Ivermectin to HCQ and AZT proved to: A) better effectiveness B) shorter hospital stay, and C) relat...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

Personal
$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
Professional
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee